H.C. Wainwright upgraded Kyverna Therapeutics (KYTX) to Buy from Neutral with a $5 price target The company is set to produce three sets of data through mid-2025, with potential opportunity to demonstrate success across three KYV-101 pipeline programs, the analyst tells investors in a research note. Ahead of the three catalysts, the firm thinks the stock’s risk/reward profile attractive, “particularly given a deeply negative enterprise value.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics: Strong Clinical Progress and Regulatory Alignment Support Buy Rating
- Kyverna Therapeutics Reports Q1 2025 Progress and Outlook
- Kyverna Therapeutics: Strategic Advancements and Clinical Progress Drive Buy Rating
- Kyverna Therapeutics reports Q1 EPS ($1.03), consensus ($1.00)
- Kyverna Therapeutics price target lowered to $4 from $6 at H.C. Wainwright